Clinical trials: Kidney Transplant Immunosuppression
Kidney Transplantation, Chronic Kidney Failure
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with efalizumab early after transplantation in…
- Trial name
- NCT00472082
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Aspergillosis
Surveillance of Fungal Infections During Construction Activity
Fungal infections in immunocompromised patients occuring during construction activities in hospitals have repeatedly been reported.
- Trial name
- NCT00473252
- Where
- Switzerland
- Volunteers
- 340 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Renal Transplant Recipients
Research Study of ATG and Rituximab in Renal Transplantation
The purpose of this study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long term immunosuppressive medication.
- Trial name
- RESTARRT (NCT01318915)
- Testing
- ATG, Rituximab, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant
The purpose of this study is to determine the effects of sirolimus in the phenotype of peripheral blood T and B lymphocytes regarding their naïve, memory, effector end regulatory phenotype and in the development of anti-HLA…
- Trial name
- NCT02208791
- Testing
- Sirolimus, No intervention
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- University of Sao Paulo General Hospital
Immunosuppression
Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients
Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
- Trial name
- NCT02953873
- Testing
- Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Medical University of South Carolina
Simultaneous Kidney and Pancreas Transplantation
Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
The purpose of this study is to find out if the drug NULOJIX® (belatacept) will minimize the amount of other anti-rejection medications necessary and thereby reduce the long-term side effects caused by the other medications.
- Trial name
- NCT01790594
- Testing
- Belatacept, methylprednisolone, Anti-thymocyte Globulin (Rabbit)
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
Islet Cell Transplant for Type 1 Diabetes
City of Hope National Medical Center, located in Duarte, CA, is hosting a clinical study on islet cell transplantation, an experimental procedure being evaluated as a treatment for patients with type 1 diabetes.
- Trial name
- TCD (NCT01909245)
- Testing
- Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Kidney Transplant; Complications, Immunosuppression
The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation
Solid organ transplantation is the treatment of choice for patients suffering from end-stage organ disease, including for chronic kidney failure.
- Conditions
- Kidney Transplant; Complications, Immunosuppression, Transplant Failure
- Trial name
- NCT04360031
- Testing
- Tacrolimus
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Université Catholique de Louvain
Kidney Transplantation
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients
A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients
- Trial name
- NCT00282230
- Testing
- FK778
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Inc
Medication Adherence, Kidney Transplantation
Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3
Medication non-adherence is a major problem in kidney transplant recipients; young people 12-24 years of age are at particularly high risk for non-adherence and graft failure compared to young children and adults.
- Trial name
- NCT04288271
- Testing
- Adherence Intervention, Healthy living education intervention
- Where
- 8 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Renal Transplant Rejection, Kidney Transplant Failure and Rejection
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
This is a one year, prospective, randomized, open-label trial examining once versus twice daily tacrolimus dosing regimen using two preparations, extended-release Tacrolimus (Envarsus XR) versus twice daily Tacrolimus (Prograf).
- Trial name
- NCT03511560
- Testing
- Tacrolimus Extended Release Oral Tablet, Tacrolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Renal Transplant Recipients, Elderly Patients
RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients
Open label, randomized, multicenter, intervention trial comparing standard immunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen in combination with everolimus.
- Conditions
- Renal Transplant Recipients, Elderly Patients, Immunosuppression
- Trial name
- OPTIMIZE (NCT03797196)
- Testing
- low dose tacrolimus in combination with everolimus, standard dose tacrolimus with mycophenolate mofetil
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 374 people
- Sponsor
- University Medical Center Groningen
Asses Immunosuppression Modulation on Renal Recovery Post LT
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard…
- Trial name
- NCT04104438
- Testing
- Basiliximab 20 MG
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Fady M Kaldas, M.D., F.A.C.S.
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Kidney Transplant
Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity T Cell Population
This is an observational multi-center study to determine whether any single immune monitoring test or a combination of tests obtained in the first 6 months after renal transplantation correlates with acute rejection or graft loss…
- Trial name
- NKG2D (NCT01914354)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
KIDNEY TRANSPLANTATION
Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys
The purpose of this study is to explore the safety and efficacy of two different immunosuppressive regimens (sequential tacrolimus/mycophenolate mofetil [MMF] plus steroids versus tacrolimus plus MMF, following induction with…
- Trial name
- TIGRE (NCT00321113)
- Testing
- tacrolimus, mycophenolate mofetil, steroids
- Where
- 14 sites in Italy
- Volunteers
- 142 people
- Sponsor
- Astellas Pharma Inc
Transplant Recipient (Kidney), Steroid-Free Maintenance Immunosuppression
Studies of Kidney Transplant Outcome
The purpose of this study is to improve outcome for kidney transplant recipients. There has not been commensurate improvement in medium and long-term outcomes. Ongoing clinical research is necessary to improve transplant outcomes.
- Conditions
- Transplant Recipient (Kidney), Steroid-Free Maintenance Immunosuppression, Post-Transplant Infections, Thymoglobulin
- Trial name
- NCT01277770
- Testing
- Steroid-Free Maintenance Immunosuppression, Infection After Kidney Transplantation, Evaluation of the DGF nomogram in Thymoglobulin
- Where
- United States
- Volunteers
- 7,500 people
- Sponsor
- University of Minnesota
Kidney Transplantation
Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation
We have previously defined factors that predict the long term success of maintenance CsA monotherapy (CsAm) after kidney transplantation : donor age < 40 years, serum creatinine level at the initiation of CsAm £ 125 µmol/L, no…
- Trial name
- NCT00461825
- Testing
- Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups, Group A: CsA + Azathioprine(1 to 2 mg/kg/day), Group B: CsA + CellCept(500 mg x 2/day)
- Where
- 5 sites in France
- Volunteers
- 207 people
- Sponsor
- Poitiers University Hospital
Covid19
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or to reduce the severity of illness if given as prophylaxis.
- Trial name
- PROTECT-V (NCT04870333)
- Testing
- Niclosamide, Ciclesonide, Sotrovimab
- Where
- 45 sites in United Kingdom
- Volunteers
- 2,240 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust